Cyclerion Therapeutics, Inc. KRSA
31.00
(6.19)
(16.64%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 0.0×
Follow KRSA
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(24.80%) | (39.34%) | (67.77%) | (98.22%) | |
| (22.77%) | (36.07%) | (57.50%) | (82.29%) | ||
ROIC |
(45.69%) | (53.18%) | (105.93%) | (115.40%) | |
Return on Tangible Assets |
(52.51%) | (94.46%) | (366.13%) | 2,550.19% | |
Average Days of Receivables |
12.78 | 175.99 | — | — | |
Free Cash Flow per Share |
(2.98) | (7.29) | (5.98) | (7.45) | |
Free Cash Flow |
(1.37) | (3.31) | (3.59) | (4.52) | |
Capital Expenditures |
— | — | (0.07) | (0.07) | |
Piotroski F-Score |
4.00 | 2.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(9.75%) | (26.89%) | (36.63%) | (68.71%) | |
Accounts Receivable Turnover |
39.65 | 2.67 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
17.37% | 46.24% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
209.88% | 293.54% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
16.39% | 21.26% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.63 | 0.94 | 0.67 | 0.66 | |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Revenue per Share |
6.19 | 4.56 | 0.00 | 0.00 | |
Operating CF per Share |
(2.98) | (7.29) | (5.86) | (7.33) | |
Capex per Share |
0.00 | 0.00 | (0.12) | (0.12) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(77.02%) | (170.11%) | 0.00% | 0.00% |
Columns are period end dates